Predictive role of diffusion‐weighted whole‐body MRI (DW‐MRI) imaging response according to MY‐RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry

Autor: Angelo Belotti, Rossella Ribolla, Valeria Cancelli, Alberta Villanacci, Valentina Angelini, Marco Chiarini, Viviana Giustini, Giulia V. Facchetti, Aldo M. Roccaro, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Claudia Crippa, Monica Micilotta, Barbara Frittoli, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cancer Medicine, Vol 10, Iss 17, Pp 5859-5865 (2021)
Druh dokumentu: article
ISSN: 2045-7634
DOI: 10.1002/cam4.4136
Popis: Abstract Background Diffusion‐weighted whole‐body MRI (DW‐MRI) is increasingly used in the management of multiple myeloma (MM) patients, but data regarding the prognostic role of DW‐MRI imaging response after treatment are lacking. The Myeloma Response Assessment and Diagnosis System (MY‐RADS) imaging recommendations recently proposed the criteria for response assessment category (RAC) with a 5‐point scale in order to standardize response assessment after therapy, but this score still needs to be validated. Methods We investigated the prognostic role of RAC criteria in 64 newly diagnosed MM patients after autologous stem cell transplantation (ASCT), and we combined the results of MY‐RADS with those of minimal residual disease (MRD) assessment by multiparametric flow cytometry (MFC). Results Superior post‐ASCT PFS and OS were observed in patients with complete imaging response (RAC1), with respect to patients with imaging residual disease (RAC≥2): median PFS not reached (NR) versus 26.5 months, p = 0.0047, HR 0.28 (95% CI: 0.12–0.68); 3‐year post‐ASCT OS 92% versus 69% for RAC1 versus RAC ≥2, respectively, p = 0.047, HR 0.24 (95% CI: 0.06–0.99). Combining MRD and imaging improved prediction of outcome, with double‐negative and double‐positive features defining groups with excellent and dismal PFS, respectively (PFS NR vs. 10.6 months); p = 0.001, HR 0.07 (95%CI: 0.01–0.36). Conclusion The present study supports the applicability of MY‐RADS recommendations after ASCT; RAC criteria were able to independently stratify patients and to better predict their prognosis and the combined use of DW‐MRI with MFC allowed a more precise evaluation of MRD.
Databáze: Directory of Open Access Journals